Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
factor VIII-loaded tolerogenic dendritic cells
- Development stage
- Phase 1
- Lead developer
- CELLforCURE
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Factor VIII-loaded tolerogenic dendritic cells (tolDCs) are an autologous cell therapy being developed by Cell4Cure AB for the treatment of hemophilia A in patients who have developed inhibitory antibodies (inhibitors) against exogenous Factor VIII. The therapy involves isolating a patient's own monocytes, differentiating them into dendritic cells in vitro, and treating them with immunosuppressive agents (such as dexamethasone and vitamin D3) to induce a tolerogenic phenotype. These cells are then pulsed or loaded with recombinant Factor VIII. When re-administered to the patient via intravenous infusion, these tolDCs are designed to present Factor VIII antigens to T cells in a non-stimulatory context, thereby inducing regulatory T cells (Tregs) and promoting immune tolerance, ultimately reducing or eliminating the inhibitory antibody response.
- Other names
- FVIII-tolDCAutologous tolerogenic dendritic cells loaded with Factor VIII
02
Targets
F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on factor VIII-loaded tolerogenic dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on factor VIII-loaded tolerogenic dendritic cells.